Press Release: Organon Canada Announces the Appointment of Dominic BÉGIN as President and Managing Director

Dow Jones
07/22

25-year industry leader to drive continued growth and expand access to medicines in Canada

KIRKLAND, QC, July 22, 2026 /CNW/ -- Organon Canada, a global healthcare company dedicated to improving the health of women, is pleased to announce the appointment of Dominic Bégin as President and Managing Director. In this role, Mr. Bégin will lead the organization's strategic and commercial agenda, strengthen its leadership in key therapeutic areas, and expand access to cost-effective solutions, including biosimilars, for governments and payers across Canada.

"I am honoured to take on this role and continue building on the strong foundation established since Organon's launch in Canada," said Dominic Bégin. "Together with our leadership team and colleagues across the organization, we will focus on expanding Organon's presence in Canada, unlocking new opportunities, and helping expand access to healthcare options for patients nationwide."

A founding member of Organon Canada's leadership team since 2021, Mr. Bégin has played a key role in shaping the company's distinctive culture and build its Biosimilars franchise into a recognized market leader. He is known for translating strategy into results, developing high-performing teams, and building trusted partnerships across the healthcare ecosystem.

"Dominic is a values-driven leader with a consistent track record of delivering results while building inclusive, purpose-driven teams," said Litsa Spiridonakos, Head of Human Resources, Organon Canada. "His strategic mindset, deep industry expertise, and collaborative approach will be critical as we continue to expand access to medicines and advance our leadership in women's health."

Mr. Bégin brings more than 25 years of pharmaceutical experience in Canada, spanning a series of roles with increasing scope and responsibility. Most recently, he served as Executive Director of Organon Canada's Biosimilars and Biologics franchise, where he delivered sustained double-digit growth, launched multiple products, and helped expanding patient access to more affordable treatments, generating meaningful savings for Canada's healthcare system.

Mr. Bégin holds a B.Sc. in Biology from the Université de Sherbrooke and has completed multiple business and professional certifications.

About Organon

Organon $(OGN)$ is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women's Health, Biosimilars and General Medicines, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. For more information, visit https://www.organon.com/canada-en/ and connect with us on LinkedIn.

SOURCE Organon Canada Inc.

/CONTACT:

Copyright CNW Group 2026 
 

(END) Dow Jones Newswires

July 22, 2026 08:02 ET

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10